United StatesDopamine HCl Injection, USP 200 mg/5 mL (40 mg/mL) 5 mL single‑dose vials (25 vials per tray), Vial NDC 0409-5820-11, Carton NDC 0409-5820-01, Lot # NL5230, Exp Date 10/2027, distributed by Hospira, Inc., is being recalled by Pfizer. The product was recalled nationwide in the United States due to lack of assurance of sterility; the recall is ongoing.
What's being recalled
Dopamine HCl Inj., USP, 200 mg/5 mL (40 mg/mL), 5 mL Single-dose, 25 vials per tray, Rx only, Distributed by Hospira, Inc., Lake Forest, IL 60045 USA, Vial NDC 0409-5820-11, Carton NDC 0409-5820-01.
Recalling firm: Pfizer, Manhattan, NY, United States.
How to identify it
Lot # NL5230, Exp Date:10/2027
The hazard
Lack of Assurance of Sterility
What to do
Don't stop taking a prescribed medicine without talking to your doctor or pharmacist first. For other products, stop using them and ask the pharmacist, seller or maker what to do.
The notice doesn't give instructions for consumers, so this is general advice for health & beauty recalls. Check the official notice for the details.
Where it was sold
US Nationwide.
The official notice
This page is a summary of the notice published by U.S. Food and Drug Administration (enforcement reports), collected from U.S. Food and Drug Administration (enforcement reports). Check the original before you act on it.
Read the official notice (opens in a new tab)